Trial · NCT07884240
A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
NCT07884240, Phase 3, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women. Trials, record NCT07884240. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884240
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
- NCT number
- NCT07884240
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 580 participants, estimated
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Sexually Transmitted Infection (STI), Gonorrhea, Syphilis, Chlamydia
- Interventions
- Doxycycline hyclate, Standard of Care for STI prevention
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Rate of Composite Incident STI events | Testing will occur at each quarterly visit (week 13, 26, 39 and 52). | Nucleic acid amplification test (NAAT) from all sites (vaginal, rectal, oropharyngeal) or newly positive or four-fold rise in RPR titers |
| Secondary | The Rate of Incident Chlamydia Trachomatis (CT) Infection | Testing will occur at each quarterly visit (week 13, 26, 39 and 52). | Nucleic Acid Amplification Test (NAAT) From All Sites (vaginal, rectal, oropharyngeal) |
| Secondary | The Rate of Incident Neisseria Gonorrhoeae (NG) Infection | Testing will occur at each quarterly visit (week 13, 26, 39 and 52). | Nucleic Acid Amplification Test (NAAT) From All Sites (vaginal, rectal, oropharyngeal) |
| Secondary | The Rate of Incident Early Syphilis Infection | Testing will occur at each quarterly visit (week 13, 26, 39 and 52). | Newly Positive or Four-Fold Rise in Rapid Plasma Reagin (RPR) Titers From All Sites (vaginal, rectal, oropharyngeal) |
| Secondary | The Rate of Incident NG Infection | Testing will occur at each quarterly visit (week 13, 26, 39 and 52). | Nucleic Acid Amplification Test (NAAT) From Rectal or Pharyngeal Site |
| Secondary | The Rate of Incident CT Infection | Testing will occur at each quarterly visit (week 13, 26, 39 and 52). | Nucleic Acid Amplification Test (NAAT) From Rectal or Pharyngeal Site |
| Secondary | The Number of Doxycycline-specific Side Effects | Week 0 through Week 52 | Such as gastrointestinal upset, photosensitivity, esophageal irritation, and skin reactions |
| Secondary | The Number of Participants who discontinue study due to side effects | Week 0 through Week 52 | |
| Secondary | Number of Participants with Serious Adverse Events (SAEs) | Week 0 through Week 52 | |
| Secondary | Number of Participants with Adverse Events (AEs) | Week 0 through Week 52 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884240
GET https://conductscience.org/api/trials/v1/NCT07884240/registered